Abstract
Classical benzodiazepines (BZDs) bind at the high-affinity BZD binding site of the GABAA receptor and enhance the natural effect of GABA resulting in anxiolytic, anticonvulsant, muscle relaxation and sedative effects. However, BZDs have unwanted side effects due to drug interaction, abuse and dependence. In addition, GABAA receptor variants exhibit poor affinity for BZDs and could lead to pharmaco-resistance. Using virtual screening and in silico molecular docking, we have identified novel compounds with a high affinity towards the BZD binding site of the GABAA receptor. In addition, we have also identified compounds showing high affinity towards the H129Y GABAA variant, which could act as novel personalised medicines. We have predicted physiochemical, pharmacokinetics and drug-likeness properties of the high-affinity compounds. Further in vitro and in vivo validation could identify novel lead compounds against the BZD allosteric binding site of wild-type and H129Y GABAA receptor variants.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Computational Biology and Drug Design
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
